Boston Scientific enters $2 billion accelerated share repurchase

Boston Scientific said on Monday it entered into a $2 billion accelerated share repurchase agreement with JPMorgan Chase Bank, National Association, under its existing stock buyback authorization.

The company said it expects to receive about 30.4 million shares initially, based on the May 15, 2026 closing price of $52.68. Final settlement is expected by June 30, 2026.

The repurchase is part of Boston Scientific's previously announced $5 billion share repurchase authorization. After the ASR is completed, the company said about $3 billion would remain available under that authorization.

An accelerated share repurchase allows a company to return cash to shareholders more quickly by buying stock through a bank counterparty while the final share count is later determined by the average market price during the term of the agreement.

The announcement adds another capital-allocation move for Boston Scientific, which has been using its buyback authorization in a sizable one-time transaction rather than through routine open-market repurchases.